Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial

Fong, Youyi; Huang, Yunda; Benkeser, David; N. Carpp, Lindsay; Áñez, Germán; Woo, Wayne; McGarry, Alice; M. Dunkle, Lisa; Cho, Iksung; R. Houchens, Christopher; Martins, Karen; Jayashankar, Lakshmi; Castellino, Flora; J. Petropoulos, Christos; Leith, Andrew; Haugaard, Deanne; Webb, Bill; Lu, Yiwen; Yu, Chenchen; Borate, Bhavesh; W. P. van der Laan, Lars; S. Hejazi, Nima; K. Randhawa, April; P. Andrasik, Michele; G. Kublin, James; Hütter, Julia; Keshtkar‐Jahromi, Maryam; Beresnev, Tatiana; Corey, Lawrence; M. Neuzil, Kathleen; Follmann, Dean; A. Ake, Julie; L. Gay, Cynthia; L. Kotloff, Karen; A. Koup, Richard; O. Donis, Rubén; B. Gilbert, Peter; Assays Team, Immune; Vaccine Prevention Network (CoVPN)/2019nCoV-301 Principal Investigators and Study Team, Coronavirus; States Government (USG)/CoVPN Biostatistics Team, United

doi:10.1038/s41467-022-35768-3

Public

Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial

Published in Nature Communications • Jan 19, 2023

Authors:

Youyi Fong

Yunda Huang

David Benkeser

Abstract

In the PREVENT-19 phase 3 trial of the NVX-CoV2373 vaccine (NCT04611802), anti-spike binding IgG concentration (spike IgG), anti-RBD binding IgG concentration (RBD IgG), and pseudovirus 50% neutralizing antibody titer (nAb ID50) measured two weeks post-dose two are assessed as correlates of risk and...

Subject

Medicine

Coronavirus disease 2019 (COVID-19)

Vaccine efficacy

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!